Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00045721 · ClinicalTrials.gov registry record · Phase 1
Carmustine Implants and O(6)-Benzylguanine in Treating Children With Recurrent Malignant Glioma
A Phase 1 study, sponsored by Pediatric Brain Tumor Consortium.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT00045721 is a Phase 1 study that was terminated before completion, run by Pediatric Brain Tumor Consortium. The registered enrollment target is 3 participants.
The verdict
NCT00045721, a Phase 1 study, was terminated before completion, sponsored by Pediatric Brain Tumor Consortium.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemotherapy placed into the surrounding tissue after surgery to remove the tumor may kill any remaining tumor cells. O(6)-benzylguanine may increase the effectiveness of carmustine by making tumor cells more sensitive to the drug. PURPOSE: Phase I trial to study the safety of combining O(6)-benzylguanine with carmustine implants in treating children who have recurrent malignant glioma.
Interventions
- DRUG O6-benzylguanine
- PROCEDURE conventional surgery
- PROCEDURE adjuvant therapy
- PROCEDURE neoadjuvant therapy
- DRUG polifeprosan 20 with carmustine implant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2003-03 |
| Est. Completion | 2004-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00045721
The ClinicalTrials.gov registry entry for NCT00045721 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pediatric Brain Tumor Consortium, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which O6-benzylguanine is the first listed.
NCT00045721 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00045721 about?
NCT00045721 is a clinical study titled "Carmustine Implants and O(6)-Benzylguanine in Treating Children With Recurrent Malignant Glioma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemotherapy placed into the surrounding tissue after surgery to remove the tumor may kill any remaining tumor cells. O(6)-benzylguanine may increase the effectiveness of carmustin...
What is the current status of trial NCT00045721?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2003-03. Estimated completion is 2004-07.
What interventions are being tested in trial NCT00045721?
The interventions under investigation include: O6-benzylguanine (DRUG), conventional surgery (PROCEDURE), adjuvant therapy (PROCEDURE), neoadjuvant therapy (PROCEDURE), polifeprosan 20 with carmustine implant (DRUG).
Who is sponsoring clinical trial NCT00045721?
This trial is sponsored by Pediatric Brain Tumor Consortium, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.